Lartruvo (olaratumab)

drip
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Lartruvo (olaratumab)

How to buy Lartruvo: You can order Lartruvo (olaratumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Eli Lilly and Co.
Disease Soft-tissue Sarcoma
Indication Soft-tissue Sarcoma
Mode of Action Platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody
Approval Status EMA approved (EU); FDA approved (USA)
CAS Number 1024603-93-7
Strength 10 mg/mL

Who is olaratumab for?

Lartruvo (olaratumab) is indicated in combination with doxorubicin for the treatment of patients with soft tissue sarcoma (STS) who cannot undergo surgery or radiotherapy (treatment with radiation) and who have not been previously treated with doxorubicin [1][2]. Doxorubicin is a cancer medication widely approved for the treatment of different forms of cancer [5][6][7].

Recommended dose

Complete information about Lartruvo (olaratumab) dosage and administration can be found here [1][3].
The standard dosage is:
  • 15 mg / kg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.
  • Administer in combination with doxorubicin for up to 8 cycles of treatment, followed by Lartruvo monotherapy in patients whose disease has not progressed. Doxorubicin is given on day 1 of each cycle following the Lartruvo (olaratumab) infusion.
Consult your treating doctor for personalised dosing.

What is olaratumab and how does it work?

Lartruvo (olaratumab) is a cancer medicine used to treat adults with advanced soft tissue sarcoma, a type of cancer that affects the soft, supportive tissues of the body such as muscles, blood vessels, and fat tissue [2]. The active substance in Lartruvo, olaratumab, is a monoclonal antibody that has been designed to recognise and attach to a protein called ‘platelet-derived growth factor receptor alpha’ (PDGFRα). This protein is often found on the surface of cells where it plays a role in regulating cell multiplication. In cancers such as soft tissue sarcoma, this protein is present in high levels or is overactive, causing cells to become cancerous. By attaching to PDGFRα on sarcoma cells, Lartruvo is expected to block the activity of this protein, thereby slowing down the growth of the cancer [2].

What is olaratumab's approval status?

Lartruvo (olaratumab) was approved by:
  • FDA (USA) on October 1, 2016
  • EMA (EU) on November 9, 2016
for the treatment of patients with soft tissue sarcoma (STS)  who cannot undergo surgery or radiotherapy (treatment with radiation) and who have not been previously treated with doxorubicin [2][3][4]
The approvals were based on a study involving 133 adults with advanced soft tissue sarcoma who couldn’t undergo surgery or radiotherapy and who had not been previously treated with anthracyclines (a group of cancer medicines that includes doxorubicin) [2][3][4]. Patients in this trial who received olaratumab with doxorubicin had a statistically significant improvement in overall survival: the median survival was 26.5 months compared to 14.7 months for patients who received doxorubicin alone. Patients who received Lartruvo with doxorubicin had a median progression-free survival (time patients live without their disease getting worse) of 6.6 months compared to 4.1 months for patients who received doxorubicin alone. Tumor shrinkage was 18.2 % for patients who received Lartruvo (olaratumab) with doxorubicin and 7.5 % for those who received doxorubicin alone [3][4].
The most common adverse reactions of Lartruvo (olaratumab) plus doxorubicin are nausea, fatigue, musculoskeletal pain, mucositis, alopecia, vomiting, diarrhea, decreased appetite, abdominal pain, neuropathy, and headache [1][3].
References
[1] Summary of Product Characteristics [FDA]: Lartruvo (olaratumab), Eli Lilly and Co., Oct. 2016.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf
[2] EMA. EPAR summary for the public. Lartruvo (olaratumab). Nov. 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004216/WC500216872.pdf
[3] Summary of Product Characteristics [EMA]: Lartruvo (olaratumab), Eli Lilly Netherland B.V., 05/05/2017.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004216/WC500216869.pdf
[4] Tap W.D., et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. The Lancet. 2016/07/04; 388(10043):488–497.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30587-6/abstract
[5] Drugs.com. Doxorubicin. 28/12/2016 (last updated 01/06/2017), cited on 10/01/2017.
https://www.drugs.com/mtm/doxorubicin.html
[6] EMA. Human Medicines: Caelyx (doxorubicin), 09/03/2008 (last updated: 27/02/2017), cited on 10/01/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000089/human_med_000683.jsp&mid=WC0b01ac058001d124
[7] Summary of Product Characteristics: Caelyx (doxorubicin), JANSSEN-CILAG Pty Ltd., TGA, May 2016.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02041-3

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.